Specialty Vaccine Company PaxVax Appoints Philip K. Moody As Chief Financial Officer

REDWOOD CITY, Calif., Sept. 6, 2016 /PRNewswire/ -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Philip K. Moody as Chief Financial Officer (CFO) effective August 29, 2016. In this role, Mr. Moody will oversee all financial functions for the company.

"I am delighted to add someone with Philip's deep expertise and insights in both the public and private biopharmaceutical sectors to the PaxVax leadership team," said Nima Farzan, Chief Executive Officer and President, PaxVax. "His extensive background and experience leading global teams in areas of finance and operations will be a strong asset as we continue to advance the development of our product portfolio."

PaxVax has focused on the acquisition and development of vaccines for travelers. In June 2016, PaxVax received approval from the United States Food and Drug Administration for Vaxchora™, a single-dose oral, live attenuated cholera vaccine indicated for use in adults 18 to 64 years of age. In July of 2014, PaxVax acquired the FDA-approved typhoid vaccine Vivotif^® from Crucell Switzerland AG. PaxVax's pipeline includes vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika.

"I can't imagine a more exciting time to join PaxVax. As an emerging leader in the specialty vaccine space and with a focus on travel vaccines for infectious diseases with significant health burdens, PaxVax continues to build momentum and bring strong candidates to this unique market," said Mr. Moody. "I am thrilled to work closely with Nima and the entire team to continue to foster PaxVax's growth as it works to become the world's leading supplier of specialty vaccines. Furthermore, the recent investment of Cerberus Capital Management provides the financial support which will enable this vision."

Mr. Moody joins PaxVax from BTG PLC, where he served as the Chief Financial Officer for the North American sector. In this role, he served as an advisor to the Head of North America at BTG, a company valued at $5 billion, and was responsible for management and oversight of all financial functions for the British-based medical device/specialty pharmaceutical business. Prior to this role, Mr. Moody was Founder, Board Member and Chief Executive Officer for DOLORANA, Inc., where he oversaw all business functions for this preclinical company developing products for the management of inflammatory and neuropathic pain. Mr. Moody has also held senior finance roles in a number of public and private companies, including Chiron, where he was involved in their vaccines business and served as Vice President, Finance and Operations.

About PaxVax

PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases for traditionally overlooked markets such as travel. PaxVax has licensed vaccines for typhoid fever (Vivotif^®) and cholera (Vaxchora™), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. As part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.

SOURCE PaxVax, Inc.

Related Links

http://www.PaxVax.com